Right now, a fantastic tariff safe-haven stock, one that's climbed nearly 70% in three years, is offering investors a great ...

SK Capital Partners, LP ("SK Capital") and Beacon Parent Holdings, L.P. ("Parent") announced today that all required regulatory approvals to complete the previously ...

Baird & Co. Good day, and welcome to the Vertex, Inc. First Quarter 2025 Earnings Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today’s ...

Zimislecel (VX-880), fully differentiated islet cells with standard immunosuppression: Vertex previously announced that it has discontinued development of the VX-264 (“cells plus device ...

Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) were sinking 11.9% as of 10:18 a.m. ET on Tuesday. The sharp decline came after the company announced its 2025 first-quarter results on Monday evening.

Reserve your free spot now. Vertex reported first-quarter adjusted earnings per share of $4.06, down from $4.76 a year ago, missing the consensus of $4.32. The cystic fibrosis-focused company ...

Vertex Pharmaceuticals reported disappointing Q1 revenue and earnings. The company also revealed it is temporarily pausing part of a phase 1/2 study of experimental cystic fibrosis drug VX-522 ...

Siemens Energy has announced in its second quarter (Q2) earnings report that it anticipates a comparable revenue growth of 13 ...

Vertex missed Wall Street's Q1 estimates and announced a pause with an early-stage study of its mRNA cystic fibrosis drug. This biotech stock should still generate exceptional returns over the ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

Scientists are using cosmic distortions in light to test a bold idea: that the Universe might not be as symmetrical as we’ve ...